*To the Editor*:

We read with interest the recent article by Taranto-Montemurro and colleagues on the impact of atomoxetine plus oxybutynin on obstructive sleep apnea (OSA) severity ([@bib1]). Although we hope there is a potential role for this new pharmacologic approach, we are concerned about methodological choices that may introduce bias into estimates of the efficacy of this treatment.

First, there is the problem of missing data. In this crossover trial, two out of 12 subjects (17%) randomized to atomoxetine--oxybutynin as the first treatment dropped out, versus zero of 10 subjects (0%) randomized to placebo first. Such dropouts are typically differential in nature, and ignoring them by using a complete-case analysis tends to overestimate the benefits of atomoxetine--oxybutynin. Methods such as mixed-effects models that use all collected data would provide a more robust estimate of the true effect of atomoxetine--oxybutynin while also allowing for the evaluation of any crossover effects ([@bib2]).

Second, and of more concern, the authors focus on a *post hoc* analysis in which they stratified patients on the apnea--hypopnea index (AHI) while the patients were receiving a placebo (those with AHI \> 10 events/h on placebo treatment). Stratification on an observed value of the study outcome is well understood to provide biased results. Performing a comparison of atomoxetine--oxybutynin versus placebo while restricting the analysis to patients with poor results on placebo would result in a positively biased estimate of the treatment effect. If the treatment were to have no effect whatsoever, one could still create the appearance of a "positive" effect by selecting only the patients with poor results on placebo---this is a variation of the commonly known phenomenon of regression to the mean ([@bib3]). Because the AHI is known to vary from night to night ([@bib4]), restricting an analysis to subjects with the highest AHI on one night of placebo treatment results in a subgroup whose AHI would likely be lower if the subjects were simply treated with placebo for a second night. If the analysis is restricted to a subgroup of patients whose AHI on placebo is an overestimate of their true mean AHI, the effect of atomoxetine--oxybutynin in lowering the AHI compared with placebo will also be overestimated. Regression to the mean can explain why those with the highest AHI on placebo showed not only the greatest difference (atomoxetine--oxybutynin − placebo) in AHI but also the greatest differences in variables that are correlated with the AHI, such as arousal index, sleep efficiency, and sleep quality.

An alternative approach that would provide an unbiased estimate of the true effect of atomoxetine--oxybutynin would be to stratify results on the AHI determined before enrollment rather than on the AHI observed on placebo. The inclusion criteria for this study reported on [clinicaltrials.gov](http://clinicaltrials.gov) include an AHI of \>15 events/h, so presumably the authors have an AHI assessment before randomization. Surprisingly, this AHI is not reported in the article and is not used for stratification purposes. This would enable a more valid assessment of whether the response to pharmacologic therapy is greater in patients with more severe OSA.

Patients and clinicians eagerly await a pharmacologic treatment for OSA that will be better tolerated than currently available therapies. Despite the hunger for a magic cure, it is important to preserve methodological rigor to ensure that treatments are actually as effective as we say they are.

Supported by grants from the ResMed Foundation, Bayer Pharmaceuticals, and Philips Respironics (S.R.P.).

Originally Published in Press as DOI: [10.1164/rccm.201812-2277LE](http://dx.doi.org/10.1164/rccm.201812-2277LE) on February 26, 2019

[**[Author disclosures](http://www.atsjournals.org/doi/suppl/10.1164/rccm.201812-2277LE/suppl_file/disclosures.pdf)**]{.ul} are available with the text of this letter at [www.atsjournals.org](http://www.atsjournals.org).
